Skip to main content
Premium Trial:

Request an Annual Quote

Much Hoopla about HUPO


Move over, genome. As the human genome project frenzy settles down, attempts to undertake a similar proteome effort are gaining momentum.

At an early April meeting in Tysons Corner, Va., a group of academic and industry scientists met to take on the proteome challenge. Although the assembly succeeded in generating vigorous debate, it was hard pressed to agree on what exactly the Human Proteome Organization (HUPO) would oversee, or how.

Part of that stems from the fact that HUPO itself is still under development. The organization currently consists of 24 advisory members from academia and industry, but has yet to receive any federal or private funding. As this magazine went to press, co-founder Ian Humphery-Smith had spoken with a candidate for president and was about to conduct an electronic balloting.

It seems the organization will develop simultaneously with its goals. At the meeting, many scientists said HUPO should coordinate various efforts involved in proteome study — cataloging proteins, determining structure, and studying their interactions — but couldn’t agree on a means. While some academics called for HUPO to coordinate public and private researchers to prevent duplicated efforts, others (mainly industry scientists) claimed that top-down coordination would only delay science. Predictably, industry and academic scientists also disagreed on the question of free access to data.

Others countered that coordination should not necessarily be HUPO’s goal. Humphery-Smith contends that the organization should facilitate or promote the worldwide effort to study the proteome, rather than manage it. “Can we coordinate a global effort?” he asks. “Probably not. But is there a need to promote [proteomics research]? I hope the answer is yes.”

— John S. MacNeil


The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.